Uwe Platzbecker

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 621 publications

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 13, 2026

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.

Journal: Haematologica

Published: June 22, 2026

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Journal: NEJM evidence

Published: May 26, 2026

Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.

Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.

Journal: Haematologica

Published: May 14, 2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Journal: Haematologica

Published: April 20, 2026

Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone-a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone-a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT.

Journal: Bone marrow transplantation

Published: April 15, 2026

Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation.

Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation.

Journal: Bone marrow transplantation

Published: April 11, 2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Journal: Blood advances

Published: April 07, 2026

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.

Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.

Journal: Bone marrow transplantation

Published: March 20, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica

Published: March 20, 2026

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Journal: British journal of haematology

Published: March 04, 2026

Showing 1-12 of 621

Last Updated: 09/26/2026